NEUROCRINE BIOSCIENCES INC Depreciation
NEUROCRINE BIOSCIENCES INC (NBIX) reported Depreciation of $15.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC depreciation for the quarter ending 2026-06-30 was $8.40M, a 33.33% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC depreciation for the quarter ending 2026-03-31 was $7.20M, a 9.09% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC depreciation for the quarter ending 2025-12-31 was $6.40M, a 3.23% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC depreciation for the quarter ending 2025-09-30 was $6.70M, a 19.64% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC depreciation for fiscal 2025 was $26.00M, a 10.64% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC depreciation for fiscal 2024 was $23.50M, a 32.02% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC depreciation for fiscal 2023 was $17.80M, a 17.88% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC depreciation for fiscal 2022 was $15.10M, a 38.53% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $8.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $15.60M 10-Q · filed 2026-07-31 | $22.00M derived: sum of 3 quarters · filed 2026-07-31 | $28.70M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2026-03-31 | $7.20M 10-Q · filed 2026-05-05 | $13.60M derived: sum of 2 quarters · filed 2026-05-05 | $20.30M derived: sum of 3 quarters · filed 2026-05-05 | $26.60M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-12-31 | $6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $13.10M derived: sum of 2 quarters · filed 2026-02-11 | $19.40M derived: sum of 3 quarters · filed 2026-07-31 | $26.00M 10-K · filed 2026-02-11 | |
| 2025-09-30 | $6.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $13.00M derived: sum of 2 quarters · filed 2026-07-31 | $19.60M 10-Q · filed 2025-10-28 | $25.80M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-06-30 | $6.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $12.90M 10-Q · filed 2026-07-31 | $19.10M derived: sum of 3 quarters · filed 2026-07-31 | $24.70M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-03-31 | $6.60M 10-Q · filed 2026-05-05 | $12.80M derived: sum of 2 quarters · filed 2026-05-05 | $18.40M derived: sum of 3 quarters · filed 2026-05-05 | $24.80M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $11.80M derived: sum of 2 quarters · filed 2026-02-11 | $18.20M derived: sum of 3 quarters · filed 2026-02-11 | $23.50M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $5.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $12.00M derived: sum of 2 quarters · filed 2025-10-28 | $17.30M 10-Q · filed 2025-10-28 | $22.20M derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-06-30 | $6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $11.70M 10-Q · filed 2025-07-30 | $16.60M derived: sum of 3 quarters · filed 2026-02-11 | $21.20M derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-03-31 | $5.30M 10-Q · filed 2025-05-05 | $10.20M derived: sum of 2 quarters · filed 2026-02-11 | $14.80M derived: sum of 3 quarters · filed 2026-02-11 | $19.00M derived: sum of 4 quarters · filed 2026-02-11 | |
| 2023-12-31 | $4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $9.50M derived: sum of 2 quarters · filed 2026-02-11 | $13.70M derived: sum of 3 quarters · filed 2026-02-11 | $17.80M 10-K · filed 2026-02-11 | |
| 2023-09-30 | $4.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $8.80M derived: sum of 2 quarters · filed 2024-10-30 | $12.90M 10-Q · filed 2024-10-30 | $16.80M derived: sum of 4 quarters · filed 2025-02-10 | |
| 2023-06-30 | $4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $8.30M 10-Q · filed 2024-08-01 | $12.20M derived: sum of 3 quarters · filed 2025-02-10 | $16.20M derived: sum of 4 quarters · filed 2025-02-10 | |
| 2023-03-31 | $4.10M 10-Q · filed 2024-05-01 | $8.00M derived: sum of 2 quarters · filed 2025-02-10 | $12.00M derived: sum of 3 quarters · filed 2025-02-10 | $15.90M derived: sum of 4 quarters · filed 2025-02-10 | |
| 2022-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $7.90M derived: sum of 2 quarters · filed 2025-02-10 | $11.80M derived: sum of 3 quarters · filed 2025-02-10 | $15.10M 10-K · filed 2025-02-10 | |
| 2022-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $7.90M derived: sum of 2 quarters · filed 2023-10-31 | $11.20M 10-Q · filed 2023-10-31 | $14.20M derived: sum of 4 quarters · filed 2024-02-09 | |
| 2022-06-30 | $3.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $7.20M 10-Q · filed 2023-08-01 | $10.20M derived: sum of 3 quarters · filed 2024-02-09 | $13.00M derived: sum of 4 quarters · filed 2024-02-09 | |
| 2022-03-31 | $3.30M 10-Q · filed 2023-05-03 | $6.30M derived: sum of 2 quarters · filed 2024-02-09 | $9.10M derived: sum of 3 quarters · filed 2024-02-09 | $11.70M derived: sum of 4 quarters · filed 2024-02-09 | |
| 2021-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $5.80M derived: sum of 2 quarters · filed 2024-02-09 | $8.40M derived: sum of 3 quarters · filed 2024-02-09 | $10.90M 10-K · filed 2024-02-09 | |
| 2021-09-30 | $2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $5.40M derived: sum of 2 quarters · filed 2022-11-01 | $7.90M 10-Q · filed 2022-11-01 | $10.10M derived: sum of 4 quarters · filed 2023-02-09 | |
| 2021-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $5.10M 10-Q · filed 2022-08-04 | $7.30M derived: sum of 3 quarters · filed 2023-02-09 | $9.50M derived: sum of 4 quarters · filed 2023-02-09 | |
| 2021-03-31 | $2.50M 10-Q · filed 2022-05-04 | $4.70M derived: sum of 2 quarters · filed 2023-02-09 | $6.90M derived: sum of 3 quarters · filed 2023-02-09 | $9.00M derived: sum of 4 quarters · filed 2023-02-09 | |
| 2020-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $4.40M derived: sum of 2 quarters · filed 2023-02-09 | $6.50M derived: sum of 3 quarters · filed 2023-02-09 | $8.60M 10-K · filed 2023-02-09 | |
| 2020-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $4.30M derived: sum of 2 quarters · filed 2021-11-01 | $6.40M 10-Q · filed 2021-11-01 | $8.40M derived: sum of 4 quarters · filed 2022-02-11 | |
| 2020-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $4.20M 10-Q · filed 2021-08-03 | $6.20M derived: sum of 3 quarters · filed 2022-02-11 | $8.20M derived: sum of 4 quarters · filed 2022-02-11 | |
| 2020-03-31 | $2.10M 10-Q · filed 2021-05-05 | $4.10M derived: sum of 2 quarters · filed 2022-02-11 | $6.10M derived: sum of 3 quarters · filed 2022-02-11 | $7.90M derived: sum of 4 quarters · filed 2022-02-11 | |
| 2019-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $4.00M derived: sum of 2 quarters · filed 2022-02-11 | $5.80M derived: sum of 3 quarters · filed 2022-02-11 | $7.40M 10-K · filed 2022-02-11 | $7.45M 10-K · filed 2020-02-07 |
| 2019-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $3.80M derived: sum of 2 quarters · filed 2020-11-09 | $5.40M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $3.40M 10-Q · filed 2020-08-03 | |||
| 2019-03-31 | $1.60M 10-Q · filed 2020-05-06 | ||||
| 2018-12-31 | $4.00M 10-K · filed 2021-02-05 | ||||
| 2017-12-31 | $2.40M 10-K · filed 2020-02-07 | ||||
| 2016-12-31 | $1.50M 10-K · filed 2019-02-08 | ||||
| 2015-12-31 | $1.00M 10-K · filed 2018-02-13 | ||||
| 2014-12-31 | $800.00K 10-K · filed 2017-02-14 | ||||
| 2013-12-31 | $700.00K 10-K · filed 2016-02-11 | ||||
| 2012-12-31 | $700.00K 10-K · filed 2015-02-09 | ||||
| 2011-12-31 | $700.00K 10-K · filed 2014-02-11 | ||||
| 2010-12-31 | $1.40M 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |